70 related articles for article (PubMed ID: 19959103)
1. C/EBPα and MYB regulate FLT3 expression in AML.
Volpe G; Walton DS; Del Pozzo W; Garcia P; Dassé E; O'Neill LP; Griffiths M; Frampton J; Dumon S
Leukemia; 2013 Jul; 27(7):1487-96. PubMed ID: 23340802
[TBL] [Abstract][Full Text] [Related]
2. CEBPA bZIP in-frame mutations in acute myeloid leukemia: prognostic and therapeutic implications.
Zhang F; Shen Z; Xie J; Zhang J; Wu Q; Jiang R; Zhao X; Yang X; Chen S
Blood Cancer J; 2024 Apr; 14(1):59. PubMed ID: 38594276
[No Abstract] [Full Text] [Related]
3. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
4. A drug-biomarker interaction model to predict the key targets of Scutellaria barbata D. Don in adverse-risk acute myeloid leukaemia.
Wang T; Lyu CY; Jiang YH; Dong XY; Wang Y; Li ZH; Wang JX; Xu RR
Mol Divers; 2021 Nov; 25(4):2351-2365. PubMed ID: 32676746
[TBL] [Abstract][Full Text] [Related]
5. Investigating the microRNA-mRNA regulatory network in acute myeloid leukemia.
Zhang H; Zhang C; Feng R; Zhang H; Gao M; Ye L
Oncol Lett; 2017 Oct; 14(4):3981-3988. PubMed ID: 28989535
[TBL] [Abstract][Full Text] [Related]
6. Significance of oncogenes and tumor suppressor genes in AML prognosis.
Kavianpour M; Ahmadzadeh A; Shahrabi S; Saki N
Tumour Biol; 2016 Aug; 37(8):10041-52. PubMed ID: 27179964
[TBL] [Abstract][Full Text] [Related]
7. The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia.
Eriksson A; Hermanson M; Wickström M; Lindhagen E; Ekholm C; Jenmalm Jensen A; Löthgren A; Lehmann F; Larsson R; Parrow V; Höglund M
Blood Cancer J; 2012 Aug; 2(8):e81. PubMed ID: 22864397
[TBL] [Abstract][Full Text] [Related]
8. Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031.
Meshinchi S; Hunger SP; Aplenc R; Adamson PC; Jessup JM
Clin Cancer Res; 2012 Mar; 18(6):1547-54. PubMed ID: 22422407
[TBL] [Abstract][Full Text] [Related]
9. Distinctive microRNA signature is associated with the diagnosis and prognosis of acute leukemia.
Zhu YD; Wang L; Sun C; Fan L; Zhu DX; Fang C; Wang YH; Zou ZJ; Zhang SJ; Li JY; Xu W
Med Oncol; 2012 Dec; 29(4):2323-31. PubMed ID: 22209839
[TBL] [Abstract][Full Text] [Related]
10. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.
Vergez F; Green AS; Tamburini J; Sarry JE; Gaillard B; Cornillet-Lefebvre P; Pannetier M; Neyret A; Chapuis N; Ifrah N; Dreyfus F; Manenti S; Demur C; Delabesse E; Lacombe C; Mayeux P; Bouscary D; Recher C; Bardet V
Haematologica; 2011 Dec; 96(12):1792-8. PubMed ID: 21933861
[TBL] [Abstract][Full Text] [Related]
11. Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice.
Li L; Bailey E; Greenblatt S; Huso D; Small D
Blood; 2011 Nov; 118(18):4935-45. PubMed ID: 21908433
[TBL] [Abstract][Full Text] [Related]
12. The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia.
Nahajevszky S; Andrikovics H; Batai A; Adam E; Bors A; Csomor J; Gopcsa L; Koszarska M; Kozma A; Lovas N; Lueff S; Matrai Z; Meggyesi N; Sinko J; Sipos A; Varkonyi A; Fekete S; Tordai A; Masszi T
Haematologica; 2011 Nov; 96(11):1613-8. PubMed ID: 21791467
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in pediatric acute myeloid leukemia.
Radhi M; Meshinchi S; Gamis A
Curr Hematol Malig Rep; 2010 Oct; 5(4):200-6. PubMed ID: 20652454
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in AML in relation to (ab)normal karyotype.
Stone RM
Best Pract Res Clin Haematol; 2009 Dec; 22(4):523-8. PubMed ID: 19959103
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia.
Ishikawa Y; Kiyoi H; Tsujimura A; Miyawaki S; Miyazaki Y; Kuriyama K; Tomonaga M; Naoe T
Eur J Haematol; 2009 Aug; 83(2):90-8. PubMed ID: 19309322
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
17. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
18. Clinically useful prognostic factors in acute myeloid leukemia.
Ferrara F; Palmieri S; Leoni F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):181-93. PubMed ID: 17996460
[TBL] [Abstract][Full Text] [Related]
19. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.
Marcucci G; Haferlach T; Döhner H
J Clin Oncol; 2011 Feb; 29(5):475-86. PubMed ID: 21220609
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
